l-γ-Glutamyl-p-nitroanilide (GPNA) is widely used to inhibit the glutamine transporter ASCT2, although it is known that it also inhibits other sodium-dependent amino acid transporters. In a panel of human cancer cell lines, which express the system l transporters LAT1 and LAT2, GPNA inhibits the sodium-independent influx of leucine and glutamine. The kinetics of the effect suggests that GPNA is a low affinity, competitive inhibitor of system l transporters. In Hs683 human oligodendroglioma cells, the incubation in the presence of GPNA, but not ASCT2 silencing, lowers the cell content of leucine. Under the same conditions the activity of mTORC1 is inhibited. Decreased cell content of branched chain amino acids and mTORC1 inhibition are observed in most of the other cell lines upon incubation with GPNA. It is concluded that GPNA hinders the uptake of essential amino acids through system l transporters and lowers their cell content.
GPNA Leucine System lLAT1 ASCT2 Glutamine
This is a preview of subscription content, log in to check access
MC, CS, GT, and MGB performed the experiments. RA performed LC/MS–MS analysis. MC analyzed the data. MC and OB designed the study and wrote the manuscript. NG discussed the results and revised the text. All Authors have approved the final version.
Compliance with ethical standards
MC is supported by a research fellowship of the University of Parma.
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any study with human participants or animals performed by any of the authors.
Barollo S, Bertazza L, Watutantrige-Fernando S et al (2016) Overexpression of l-type amino acid transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors. PLoS One 11:e0156044CrossRefPubMedPubMedCentralGoogle Scholar
Bianchi MG, Franchi-Gazzola R, Reia L et al (2012) Valproic acid induces the glutamate transporter excitatory amino acid transporter-3 in human oligodendroglioma cells. Neuroscience 227:260–270CrossRefPubMedGoogle Scholar
Bolzoni M, Chiu M, Accardi F et al (2016) Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood 128:667–679CrossRefPubMedGoogle Scholar
Broer A, Rahimi F, Broer S (2016) Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells. J Biol Chem 291:13194–13205CrossRefPubMedPubMedCentralGoogle Scholar
Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169–193CrossRefPubMedGoogle Scholar
Chiu M, Tardito S, Barilli A et al (2012) Glutamine stimulates mTORC1 independent of the cell content of essential amino acids. Amino Acids 43:2561–2567CrossRefPubMedGoogle Scholar
Chiu M, Tardito S, Pillozzi S et al (2014) Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer 111:1159–1167CrossRefPubMedPubMedCentralGoogle Scholar
del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of l-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161–174CrossRefPubMedGoogle Scholar
Esslinger CS, Cybulski KA, Rhoderick JF (2005) Nγ-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem 13:1111–1118CrossRefPubMedGoogle Scholar
Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266CrossRefPubMedGoogle Scholar
Hassanein M, Hoeksema MD, Shiota M et al (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19:560–570CrossRefPubMedGoogle Scholar
Indo Y, Takeshita S, Ishii KA et al (2013) Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res 28:2392–2399CrossRefPubMedGoogle Scholar
Ishizuka Y, Kakiya N, Nawa H et al (2008) Leucine induces phosphorylation and activation of p70S6K in cortical neurons via the system l amino acid transporter. J Neurochem 106:934–942CrossRefPubMedGoogle Scholar
Kaira K, Oriuchi N, Imai H et al (2008) l-Type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 99:2380–2386CrossRefPubMedGoogle Scholar
Kanai Y, Segawa H, Miyamoto K et al (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–23632CrossRefPubMedGoogle Scholar
Lieberman BP, Ploessl K, Wang L et al (2011) PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med 52:1947–1955CrossRefPubMedGoogle Scholar
Ren P, Yue M, Xiao D et al (2015) ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol 235:90–100CrossRefPubMedGoogle Scholar
Takahashi K, Uchida N, Kitanaka C et al (2015) Inhibition of ASCT2 is essential in all-trans retinoic acid-induced reduction of adipogenesis in 3T3-L1 cells. FEBS Open Bio 5:571–578CrossRefPubMedPubMedCentralGoogle Scholar
Tang C, Tang G, Gao S et al (2016) Radiosynthesis and preliminary biological evaluation of N-(2-[18F]fluoropropionyl)-l-glutamine as a PET tracer for tumor imaging. Oncotarget 7:34100–34111PubMedPubMedCentralGoogle Scholar
van Geldermalsen M, Wang Q, Nagarajah R et al (2016) ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35:3201–3208CrossRefPubMedGoogle Scholar
Wang Q, Holst J (2015) l-Type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 5:1281–1294PubMedPubMedCentralGoogle Scholar